A propensity score‐matched, real‐world comparison of ustekinumab vs vedolizumab as a second‐line treatment for Crohn’s disease. The Cross Pennine study II

BACKGROUND: The optimal choice of biological agents after failure of anti‐tumour‐necrosis‐factor‐(TNF)α agent in Crohn’s disease (CD) is yet to be defined. AIMS: To assess the effectiveness and safety of ustekinumab compared to vedolizumab as second‐line treatment in CD patients who failed anti‐TNFα...

Descripción completa

Detalles Bibliográficos
Autores principales: Lenti, Marco Vincenzo, Dolby, Vivien, Clark, Tanya, Hall, Veronica, Tattersall, Suzanne, Fairhurst, Francesca, Kenneth, Catherine, Walker, Rachael, Kemp, Karen, Borg‐Bartolo, Simon, Limdi, Jimmy K., Taylor, Jo, Townsend, Tristan, Subramanian, Sree, Storey, Daniel, Assadsangabi, Arash, Stansfield, Catherine, Smith, Paul, Byrne, Debra, De Silvestri, Annalisa, Selinger, Christian P.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Ustekinumab Vs Vedolizumab as Secondline Therapy in Crohn's Disease
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9305775/
https://www.ncbi.nlm.nih.gov/pubmed/34935160
http://dx.doi.org/10.1111/apt.16742

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9305775/
https://www.ncbi.nlm.nih.gov/pubmed/34935160
http://dx.doi.org/10.1111/apt.16742

Ejemplares similares